News

Deal Announcements

Allozyne Adds $2 Million Venture Capital Debt

Tuesday, June 5, 2012 5:56:00 AM PDT | VentureDeal
   Seattle, Washington  --  Biotechnology company Allozyne has garnered $2 million in venture capital debt financing.

Allozyne is developing and manufacturing protein therapeutic technologies for various autoimmune diseases and cancer.

Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1